Economic burden of rheumatoid arthritis: a systematic review.

  title={Economic burden of rheumatoid arthritis: a systematic review.},
  author={Nicola J Cooper},
  volume={39 1},
OBJECTIVE To summarize the state of knowledge with regard to the economic impact of rheumatoid arthritis (RA) and to highlight any weaknesses in the work conducted to date, so as to inform future RA cost-of-illness studies. METHODS Four computerized literature databases were searched to identify all the literature relevant to this review. Seven elements indicating a quality cost-of-illness study were established and used to appraise the literature identified critically. Where possible, costs… 

Tables from this paper

Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden.
The results of the FRAIL study allow a better understanding of the real economic impact of RA for society, which increased very significantly in the last 10 years.
Direct costs related to rheumatoid arthritis: the patient perspective
Rheumatoid arthritis is associated with substantial OOPE, imposing a considerable economic burden for patients, and OOPE contribute significantly to the total health care expenditure in rheumatoids arthritis.
Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project
Data show that simple clinical and laboratory parameters can be used early in the course of IA to predict the condition’s impact on healthcare budgets and two strong significant, early predictors of total cost were identified.
Indirect costs of rheumatoid arthritis in Brazil.
Estimated costs of rheumatoid arthritis found in the population are similar to that described in more developed countries, but indirect costs were higher in patients with poor functional classes, high socioeconomic status, and men.
Costs of workups for the diagnosis of early arthritis: results of a nationwide survey.
Diagnostic workups after a first medical visit for early polyarthritis result in substantial direct costs and the great variability observed in physicians' practices point out the need for consensus on the appropriate workups for these patients.
Cost-of-illness studies of diabetes mellitus: a systematic review.
The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
Assessing annual direct and indirect costs in a prospective cohort of patients with rheumatoid arthritis in Thailand from the societal perspective found that RA consumes a significant proportion of patients' annual average incomes and poses a significant economic burden to society.
A multicenter cost-of-illness study on rheumatoid arthritis in Italy.
Considering that costs increase with RA progression, the patients who show a rapid evolution of the functional damages should be identified early based on risk indicators, and female gender and co-morbidity are associated with higher costs.
The direct medical cost of rheumatoid arthritis in Hong Kong
The direct medical cost of the management of Rheumatoid arthritis from the perspective of a public health organisation in Hong Kong was evaluated and described to reduce the need for hospitalisation and hence reduce costs.
Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs
Findings suggest that increased quality in rheumatoid arthritis care may lead to lower inpatient and outpatient hospital costs, yet the overall cost of RA care is likely to remain high because of intensive pharmacotherapy regimens.


Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study.
A multiple logistic regression model showed that greater disability and lower age increased the odds for high costs and a high total direct cost in the first 6 yr of disease is related to severe functional disability andLower age.
A multicenter study of annual health service utilization and costs in rheumatoid arthritis.
The outpatient costs, inpatient costs, and total costs were all positively related to the Health Assessment Questionnaire Disability Index, but were not associated with self-reported pain.
The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates.
  • E. Yelin
  • Medicine, Political Science
    The Journal of rheumatology. Supplement
  • 1996
We determined the average medical and indirect costs of rheumatoid arthritis (RA) from clinical and community based samples and compared those costs to those experienced by similar persons without
The cost of rheumatoid arthritis.
This paper uses the Cost of Illness (COI) framework to estimate the cost of rheumatoid arthritis (RA) to society in the year 1992-93, showing that prevalence is three times higher amongst women than men.
Costs and outcomes in rheumatoid arthritis and osteoarthritis.
Functional capacity and specific diagnosis on entry to the study were the most important determinants of arthritis-related expenditures.
Direct medical costs unique to people with arthritis.
The analyses indicated that, compared to the NA cohort both the OA and the RA prevalence cohorts incurred statistically significantly more charges, not only for the musculoskeletal disease care, but also for the care of numerous other conditions including respiratory, cardiovascular, gastrointestinal, neurological, and psychiatric conditions.
The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs.
Uncovered income losses were the greatest economic burden for individuals with chronic rheumatoid arthritis and a striking ratio of indirect to direct medical costs has important implications for medical practice and health policy.
The lifetime economic costs of rheumatoid arthritis.
  • C. Stone
  • Medicine
    The Journal of rheumatology
  • 1984
The present value of the lifetime economic costs of rheumatoid arthritis was estimated to be $20,412/case in 1977 dollars, which is nearly as great as that for stroke and coronary heart disease.
Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
RA care, in the setting of this study, was characterized by intensive treatment, especially frequent use of medications that were delivered to most patients, and cost to the managed care provider was relatively low, owing to the rarity of RA.